IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.413
NA - Nord America 3.017
AS - Asia 2.743
SA - Sud America 503
AF - Africa 81
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.768
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.890
SG - Singapore 1.326
DE - Germania 814
NL - Olanda 730
IT - Italia 648
CN - Cina 536
BR - Brasile 416
SE - Svezia 340
VN - Vietnam 256
FR - Francia 214
IE - Irlanda 139
GB - Regno Unito 129
IN - India 102
JP - Giappone 86
HK - Hong Kong 82
FI - Finlandia 72
ID - Indonesia 68
RU - Federazione Russa 67
CA - Canada 62
BD - Bangladesh 46
TR - Turchia 45
PL - Polonia 44
MX - Messico 38
KR - Corea 37
ES - Italia 36
AR - Argentina 35
UA - Ucraina 31
IQ - Iraq 26
ZA - Sudafrica 24
AT - Austria 23
PK - Pakistan 21
CZ - Repubblica Ceca 17
CH - Svizzera 14
EC - Ecuador 14
IR - Iran 14
BE - Belgio 13
EG - Egitto 13
MK - Macedonia 13
AE - Emirati Arabi Uniti 12
CO - Colombia 12
SA - Arabia Saudita 12
CI - Costa d'Avorio 11
IL - Israele 11
LT - Lituania 11
RS - Serbia 11
PH - Filippine 10
JO - Giordania 8
PA - Panama 8
UZ - Uzbekistan 8
VE - Venezuela 8
RO - Romania 7
MA - Marocco 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
BY - Bielorussia 3
CL - Cile 3
DZ - Algeria 3
GR - Grecia 3
HR - Croazia 3
KE - Kenya 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AO - Angola 2
BT - Bhutan 2
DM - Dominica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
ME - Montenegro 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GL - Groenlandia 1
Totale 9.746
Salva come PNG Salva come JPEG
Città #
Singapore 781
Amsterdam 692
Ashburn 432
Chandler 332
San Jose 328
Frankfurt am Main 155
New York 150
Rome 119
Dublin 111
Beijing 110
Los Angeles 106
Hefei 105
Milan 95
Tokyo 81
Ho Chi Minh City 77
Hong Kong 74
Dallas 73
Hanoi 69
Jakarta 64
Lauterbourg 64
Munich 56
São Paulo 45
Boston 40
Helsinki 38
San Mateo 38
Seoul 35
The Dalles 34
Marseille 33
Moscow 32
Santa Clara 32
Houston 30
Warsaw 29
Princeton 28
Kent 27
Palermo 26
Nuremberg 25
Council Bluffs 24
Denver 24
Orem 24
Buffalo 23
Poplar 23
Atlanta 22
Stockholm 22
Chicago 21
Toronto 21
Da Nang 20
Montreal 20
Ann Arbor 19
Dearborn 19
Düsseldorf 19
Paris 19
Chennai 18
London 18
Wilmington 18
Bremen 17
Mexico City 17
Brooklyn 16
San Francisco 16
Turku 16
Johannesburg 15
Nanjing 15
Cattolica 14
Nürnberg 14
Pune 14
Augusta 13
Boardman 13
Brno 13
Falkenstein 13
Vienna 13
Ankara 12
Brussels 12
Seattle 12
Shanghai 12
Abidjan 11
Belo Horizonte 11
Kish 11
Rio de Janeiro 11
Haiphong 10
Jacksonville 10
Lancaster 10
Lappeenranta 10
Manchester 10
Phoenix 10
Redwood City 10
Salamanca 10
Secaucus 10
Skopje 10
Baghdad 9
Bari 9
Bologna 9
Guangzhou 9
Mumbai 9
Amman 8
City of London 8
Menlo Park 8
Turin 8
Washington 8
Wroclaw 8
Andover 7
Brasília 7
Totale 5.458
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 947
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 498
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 322
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 309
Assessing floppy infants: a new module 201
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 189
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 187
Developmental milestones in type I spinal muscular atrophy 186
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 163
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 163
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 155
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 154
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 153
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 152
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 151
Predominant distal muscle involvement in spinal muscular atrophy 148
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 145
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 142
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 141
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 141
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 141
Longitudinal assessments in discordant twins with SMA 137
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 134
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 132
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 131
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 131
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 130
Early treatment of type II SMA slows rate of progression of scoliosis 130
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 130
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 129
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 128
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 126
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 125
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
Nusinersen in type 0 spinal muscular atrophy: should we treat? 122
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 122
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 119
Developmental milestones in type I spinal muscular atrophy 114
Clinical Variability in Spinal Muscular Atrophy Type III. 113
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 112
Sleep disorders in spinal muscular atrophy 111
Revised upper limb module for spinal muscular atrophy: Development of a new module 109
An observational study of functional abilities in infants, children, and adults with type 1 SMA 106
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 105
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 105
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 102
Development of an academic disease registry for spinal muscular atrophy 102
Risdiplam in Type 1 Spinal Muscular Atrophy 101
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 96
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 95
An observational study of functional abilities in infants, children, and adults with type 1 SMA 93
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 92
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 91
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 91
Long term follow-up of scoliosis progression in type II SMA patients 90
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 90
Longitudinal natural history of type I spinal muscular atrophy: A critical review 90
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 86
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 82
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 82
Revised upper limb module for spinal muscular atrophy: 12 month changes 77
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 75
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 73
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 73
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 70
An observational study of functional abilities in infants, children, and adults with type 1 SMA 68
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 67
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 63
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 53
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Totale 9.878
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 0 0 23 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20265.168 524 135 305 591 872 1.339 724 197 229 252 0 0
Totale 9.878